RB
PCRX icon

Rodgers Brothers’s Pacira BioSciences PCRX Stock Holding History

Rodgers Brothers’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,325
Closed -$542K – 190
2020
Q2 		$542K Buy
10,325
+200
+2% +$8.36K 0.15% 132
2020
Q1 		$339K Sell
10,125
-100
-1% -$4.15K 0.11% 149
2019
Q4 		$463K Hold
10,225
– – 0.12% 144
2019
Q3 		$389K Buy
+10,225
New +$408K 0.11% 154

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Rodgers Brothers's PCRX Position: Q3 2020 in Review

Rodgers Brothers sold out of Pacira BioSciences (PCRX) in Q3 2020, closing a stake of 10,325 shares — an estimated $542K sold.

Rodgers Brothers first reported a position in PCRX in Q3 2019 and held it in 4 quarters. The position peaked at $542K in Q2 2020. 257 funds tracked by Wall St. Rank hold PCRX as of Q3 2020.

  • Rodgers Brothers reported no remaining Pacira BioSciences position as of Q3 2020 after selling out during the quarter.
  • Rodgers Brothers sold 10,325 Pacira BioSciences shares in Q3 2020, an estimated $542K.
  • Rodgers Brothers first reported a position in Pacira BioSciences in Q3 2019 and held it in 4 quarters.
  • Rodgers Brothers's Pacira BioSciences position peaked at $542K in Q2 2020.
  • 257 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2020.

Based on Rodgers Brothers's 13F filing for Q3 2020, filed 13 Nov 2020.